Status:
RECRUITING
Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model
Lead Sponsor:
Fudan University
Conditions:
Metastasis
Predictive Cancer Model
Eligibility:
All Genders
18-75 years
Brief Summary
A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify ...
Detailed Description
Metastasis is an important biological feature of malignant tumors, and it is also the main factor affecting the outcome of cancer patients. The direct death of most cancer patients is the mass effect ...
Eligibility Criteria
Inclusion
- ECOG performance status score 0-2;
- Histologically or cytologically confirmed stage III-IV NSCLC;
- If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR/ALK/ROS1/KRAS/MET) should be performed;
- Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR/CT for colorectal cancer, and chest CT for breast cancer);
- No target organ metastasis on baseline imaging (no brain/liver/lung metastasis for lung cancer/colorectal cancer/breast cancer, respectively);
- Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;
- Regular follow-up during and after treatment;
- Life expectancy ≥6 months;
Exclusion
- Patients with indeterminate pathological type;
- Patients without baseline imaging data before treatment;
- Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer/colorectal cancer/breast cancer corresponding to brain/liver/lung metastasis);
- patients who cannot or refuse to receive regular imaging follow-up;
- Combined history of other malignant tumors;
- Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,
- Lactating or pregnant women;
- Receiving other long-term medications that may affect disease progression as assessed by a physician.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT06202404
Start Date
January 1 2024
End Date
December 1 2027
Last Update
February 9 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
2
Fudan University Shanghai Cancer Center
Shanghai, China